JNJ-64619178

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-64619178, covering 2025-12-18 to 2025-12-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS [Phase 1]

See pricing